NCT06839105 2025-05-31
A Clinical Study to Evaluate the Safety and Tolerability of AWT020 in Patients With Advanced Malignancies
Shanghai Junshi Bioscience Co., Ltd.
Phase 1 Recruiting
Clinical Trials
12 trialsNCT02009449 2024-11-15
IVY
Eli Lilly and Company
Phase 1 Completed
NCT00121251 2021-04-06
Sorafenib, Gemcitabine, and Capecitabine in Treating Patients With Unresectable and/or Metastatic Kidney Cancer
National Cancer Institute (NCI)
Phase 1/2 Completed
NCT02423954 2018-07-02
NivoPlus
Western Regional Medical Center
Phase 1/2 Terminated
NCT00496587 2017-07-19
Capecitabine, Gemcitabine, and Bevacizumab in Combination for Patients With Sarcomatoid Renal Cell Carcinoma
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00042965 2016-07-14
Capecitabine and Gemcitabine in Treating Patients With Metastatic Kidney Cancer
Alliance for Clinical Trials in Oncology
Phase 2 Completed
NCT00523640 2014-02-11
A Phase II Trial of Gemcitabine, Capecitabine, and Bevacizumab in Metastatic Renal Cell Carcinoma
University of Chicago
Phase 2 Terminated
NCT00058318 2012-11-02
S0312, Gemcitabine and Capecitabine in Treating Patients With Advanced Renal Cell (Kidney) Cancer
SWOG Cancer Research Network
Phase 2 Completed
NCT00311467 2012-05-16
Combined Treatment With Capecitabine and Immunotherapy Versus Immunotherapy Alone in Advanced Renal Cell Carcinoma
Central European Cooperative Oncology Group
Phase 3 Terminated
NCT01182142 2010-08-24
Study of Capecitabine in Metastatic Non-clear Cell Renal Cell Carcinoma (RCC) Patients
Kidney Cancer Research Bureau
Phase 2 Completed
NCT00591188 2009-05-01
Capecitabine and Interferon-Alpha in Metastatic Renal Cell Carcinoma Patients With Failure on Interleukin-2 Based Regimens
Kidney Cancer Research Bureau
Phase 2 Completed
NCT00496301 2009-01-14
SOGUG-02-06
Spanish Oncology Genito-Urinary Group
Phase 2 Completed